Woodline Partners’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,509,920
| Closed | -$30.4M | – | 1093 |
|
|
2026
Q1 | $30.4M | Sell |
1,509,920
-411,172
| -21% | -$6.63M | 0.11% | 243 |
|
|
2025
Q4 | $31M | Buy |
1,921,092
+428
| +0% | +$5.67K | 0.12% | 222 |
|
|
2025
Q3 | $23.4M | Hold |
1,920,664
| – | – | 0.11% | 250 |
|
|
2025
Q2 | $21.7M | Buy |
1,920,664
+303,195
| +19% | +$3.71M | 0.11% | 266 |
|
|
2025
Q1 | $18.7M | Buy |
1,617,469
+329,068
| +26% | +$3.36M | 0.12% | 241 |
|
|
2024
Q4 | $10.9M | Buy |
1,288,401
+680,148
| +112% | +$7.04M | 0.07% | 322 |
|
|
2024
Q3 | $7.04M | Buy |
608,253
+457,791
| +304% | +$5.76M | 0.06% | 346 |
|
|
2024
Q2 | $1.77M | Hold |
150,462
| – | – | 0.02% | 431 |
|
|
2024
Q1 | $1.78M | Sell |
150,462
-196,401
| -57% | -$2.62M | 0.02% | 431 |
|
|
2023
Q4 | $4.25M | Buy |
+346,863
| New | +$3.16M | 0.05% | 332 |
|
|
2023
Q3 | – | Sell |
-108,358
| Closed | -$975K | – | 674 |
|
|
2023
Q2 | $975K | Buy |
+108,358
| New | +$999K | 0.01% | 486 |
|
|
2023
Q1 | – | Sell |
-593,810
| Closed | -$4.01M | – | 708 |
|
|
2022
Q4 | $4.01M | Sell |
593,810
-159,071
| -21% | -$852K | 0.05% | 351 |
|
|
2022
Q3 | $10.9M | Sell |
752,881
-334,002
| -31% | -$4.67M | 0.15% | 190 |
|
|
2022
Q2 | $10.7M | Buy |
1,086,883
+589,869
| +119% | +$6.51M | 0.16% | 166 |
|
|
2022
Q1 | $7.33M | Buy |
497,014
+358,276
| +258% | +$5.15M | 0.12% | 207 |
|
|
2021
Q4 | $1.84M | Buy |
138,738
+9,387
| +7% | +$149K | 0.03% | 435 |
|
|
2021
Q3 | $2.26M | Buy |
129,351
+27,645
| +27% | +$560K | 0.04% | 395 |
|
|
2021
Q2 | $2.44M | Sell |
101,706
-122,353
| -55% | -$3.2M | 0.05% | 327 |
|
|
2021
Q1 | $5.76M | Buy |
+224,059
| New | +$5.89M | 0.13% | 179 |
|
Other funds holding KALV
Woodline Partners's KALV Position: Q2 2026 in Review
Woodline Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,509,920 shares — an estimated $30.4M sold.
Woodline Partners first reported a position in KALV in Q1 2021 and held it in 19 quarters. The position peaked at $31M in Q4 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Woodline Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Woodline Partners sold 1,509,920 KalVista Pharmaceuticals shares in Q2 2026, an estimated $30.4M.
- Woodline Partners first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 19 quarters.
- Woodline Partners's KalVista Pharmaceuticals position peaked at $31M in Q4 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.